chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Procalcitonin increased, SARS-CoV-2 test positive, Scan with contrast abnormal, Superficial vein thrombosis, Tachypnoea
Clinical narrative: Patient currently admitted at (6) days starting 11/20/2021. Patient is a 61 y.o. male who presents today with progressive shortness of breath. Began last Thursday with fatigue, cough, exertional dyspnea, and malaise. Progressed to significant shortness of breath with diarrhea for last 3 days and poor PO intake due to loss of taste. Patient has been trying to drink gatorade and eat small amounts of crackers or toast when he can but it has been challenging. He tested his oxygen saturation at home (wife works in hospice) the last few days and he was in the 80's and decided to come in. Heis vaccinated except for his booster shot, but knew he had covid19 after he was helping customers in the sporting goods store he works at who were coughing without masks around him and sounded sick. Admits some blood tinged sputum from cough 2 days prior, and watery stools. He denies chest pain, vomiting, blood in urine/stool, abdominal pain, swelling/pain in legs or extremities.    ED course: On arrival he was hypoxic at 57% and tachypneic, normotensive, aox3, breath sounds clear. He was placed on NRB which improved his saturations to around 90, and subsequently switched to HFNC 60L at FiO2 of 100% which brought his saturations up to 90's. Cultures and labs were drawn, Covid test was obtained and positive. ECG showed NSR with isolated t-wave inversion in lead 3. CXR showed extensive bilateral lung infiltrates. WBC normal, no fever. Lactate was elevated to 2.1. Procal mildly elevated. He received Decadron 6mg IV and was admitted to general floors with acute hypoxic respiratory failure secondary to covid19 pneumonia.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Ultrasound Doppler abnormal, White blood cell count normal
Clinical narrative: Patient currently admitted at (6) days starting 11/20/2021. Patient is a 61 y.o. male who presents today with progressive shortness of breath. Began last Thursday with fatigue, cough, exertional dyspnea, and malaise. Progressed to significant shortness of breath with diarrhea for last 3 days and poor PO intake due to loss of taste. Patient has been trying to drink gatorade and eat small amounts of crackers or toast when he can but it has been challenging. He tested his oxygen saturation at home (wife works in hospice) the last few days and he was in the 80's and decided to come in. Heis vaccinated except for his booster shot, but knew he had covid19 after he was helping customers in the sporting goods store he works at who were coughing without masks around him and sounded sick. Admits some blood tinged sputum from cough 2 days prior, and watery stools. He denies chest pain, vomiting, blood in urine/stool, abdominal pain, swelling/pain in legs or extremities.    ED course: On arrival he was hypoxic at 57% and tachypneic, normotensive, aox3, breath sounds clear. He was placed on NRB which improved his saturations to around 90, and subsequently switched to HFNC 60L at FiO2 of 100% which brought his saturations up to 90's. Cultures and labs were drawn, Covid test was obtained and positive. ECG showed NSR with isolated t-wave inversion in lead 3. CXR showed extensive bilateral lung infiltrates. WBC normal, no fever. Lactate was elevated to 2.1. Procal mildly elevated. He received Decadron 6mg IV and was admitted to general floors with acute hypoxic respiratory failure secondary to covid19 pneumonia.
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature increased, Fatigue, Headache, Injection site pain
Clinical narrative: Severe injection soreness, headaches, tiredness  and on  & off temperature up to 101.3
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site erythema, Injection site pain, Injection site pruritus, Injection site swelling, Injection site warmth
Clinical narrative: Red, swollen, hot, itchy sore spot on injection arm a couple of inches below injection site. Started out as small line day after injection and grown to several inches in diameter.
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: Computerised tomogram, Lymphadenopathy
Clinical narrative: I had a swollen lymph node on left side still present as of today.
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue
Clinical narrative: Tired, achy joints
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Blood glucose increased, Brain natriuretic peptide normal, COVID-19, COVID-19 pneumonia
Clinical narrative: Patient discharged after (2) day inpatient admission 11/22-11/24/2021. Patient is a 62 year male past medical history of severe chronic obstructive pulmonary disease on chronic prednisone and azithromycin (follows with Dr.), history of left upper lobe resection 2015, hypertension, prediabetes who presents today with worsening fevers shortness of breath since 11/15/2021.  Patient tested himself at home with an over-the-counter test on 11/19/2021 which was positive for COVID-19.  He is vaccinated and had his 2nd Pfizer dose 03/30/2021.  He did not yet receive the booster vaccine.  Patient's symptoms initially started with fever overall 102 F at home.     In the emergency department he was noted to be hypoxic requiring 3 L nasal cannula, worsening shortness of breath found to have acute on chronic hypoxic respiratory failure in the setting of COVID-19 pneumonia. Initial lab work notable for thrombocytopenia with platelets of 88, likely myelosuppressive manifestation of COVID-19. Chest x-ray demonstrated evidence of pneumonia with mild interstitial prominence.  He was febrile upon arrival as well to 39.4 it was given Toradol and dexamethasone.  He was admitted to Medicine no 11/22/2021 for further workup and management.   He had normal echocardiogram with EF 57% and normal BNP.  He was also noted to have sputum culture from August 2021 positive for Rhizopus and was evaluated by ID outpatient, thought to be contaminant versus colonization. He was treated with dexamethasone and remdesivir.  During his admission his oxygen requirements continued between 2 and 3 L nasal cannula.  Platelets eventually improved.  His blood glucose was mildly elevated on dexamethasone, secondary to steroid induced hyperglycemia, without need for at home insulin on discharge.  Pulmonary rehab was consulted, recommended 3 liters/minute at rest and 6 liters/minute with activity, of supplemental oxygen.  Patient instructed to complete steroid course for outpatient management of COVID-19.    Patient was discharged in stable condition, afebrile, in no acute distress, and with arranged home oxygen medical equipment and instruction of home use medical equipment.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Chest X-ray abnormal, Computerised tomogram thorax, Dyspnoea, Echocardiogram normal, Ejection fraction normal
Clinical narrative: Patient discharged after (2) day inpatient admission 11/22-11/24/2021. Patient is a 62 year male past medical history of severe chronic obstructive pulmonary disease on chronic prednisone and azithromycin (follows with Dr.), history of left upper lobe resection 2015, hypertension, prediabetes who presents today with worsening fevers shortness of breath since 11/15/2021.  Patient tested himself at home with an over-the-counter test on 11/19/2021 which was positive for COVID-19.  He is vaccinated and had his 2nd Pfizer dose 03/30/2021.  He did not yet receive the booster vaccine.  Patient's symptoms initially started with fever overall 102 F at home.     In the emergency department he was noted to be hypoxic requiring 3 L nasal cannula, worsening shortness of breath found to have acute on chronic hypoxic respiratory failure in the setting of COVID-19 pneumonia. Initial lab work notable for thrombocytopenia with platelets of 88, likely myelosuppressive manifestation of COVID-19. Chest x-ray demonstrated evidence of pneumonia with mild interstitial prominence.  He was febrile upon arrival as well to 39.4 it was given Toradol and dexamethasone.  He was admitted to Medicine no 11/22/2021 for further workup and management.   He had normal echocardiogram with EF 57% and normal BNP.  He was also noted to have sputum culture from August 2021 positive for Rhizopus and was evaluated by ID outpatient, thought to be contaminant versus colonization. He was treated with dexamethasone and remdesivir.  During his admission his oxygen requirements continued between 2 and 3 L nasal cannula.  Platelets eventually improved.  His blood glucose was mildly elevated on dexamethasone, secondary to steroid induced hyperglycemia, without need for at home insulin on discharge.  Pulmonary rehab was consulted, recommended 3 liters/minute at rest and 6 liters/minute with activity, of supplemental oxygen.  Patient instructed to complete steroid course for outpatient management of COVID-19.    Patient was discharged in stable condition, afebrile, in no acute distress, and with arranged home oxygen medical equipment and instruction of home use medical equipment.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Hyperglycaemia, Hypoxia, Interstitial lung disease, Myelosuppression, Platelet count decreased
Clinical narrative: Patient discharged after (2) day inpatient admission 11/22-11/24/2021. Patient is a 62 year male past medical history of severe chronic obstructive pulmonary disease on chronic prednisone and azithromycin (follows with Dr.), history of left upper lobe resection 2015, hypertension, prediabetes who presents today with worsening fevers shortness of breath since 11/15/2021.  Patient tested himself at home with an over-the-counter test on 11/19/2021 which was positive for COVID-19.  He is vaccinated and had his 2nd Pfizer dose 03/30/2021.  He did not yet receive the booster vaccine.  Patient's symptoms initially started with fever overall 102 F at home.     In the emergency department he was noted to be hypoxic requiring 3 L nasal cannula, worsening shortness of breath found to have acute on chronic hypoxic respiratory failure in the setting of COVID-19 pneumonia. Initial lab work notable for thrombocytopenia with platelets of 88, likely myelosuppressive manifestation of COVID-19. Chest x-ray demonstrated evidence of pneumonia with mild interstitial prominence.  He was febrile upon arrival as well to 39.4 it was given Toradol and dexamethasone.  He was admitted to Medicine no 11/22/2021 for further workup and management.   He had normal echocardiogram with EF 57% and normal BNP.  He was also noted to have sputum culture from August 2021 positive for Rhizopus and was evaluated by ID outpatient, thought to be contaminant versus colonization. He was treated with dexamethasone and remdesivir.  During his admission his oxygen requirements continued between 2 and 3 L nasal cannula.  Platelets eventually improved.  His blood glucose was mildly elevated on dexamethasone, secondary to steroid induced hyperglycemia, without need for at home insulin on discharge.  Pulmonary rehab was consulted, recommended 3 liters/minute at rest and 6 liters/minute with activity, of supplemental oxygen.  Patient instructed to complete steroid course for outpatient management of COVID-19.    Patient was discharged in stable condition, afebrile, in no acute distress, and with arranged home oxygen medical equipment and instruction of home use medical equipment.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Pulmonary oedema, Pyrexia, SARS-CoV-2 test positive, Sputum culture positive, Thrombocytopenia
Clinical narrative: Patient discharged after (2) day inpatient admission 11/22-11/24/2021. Patient is a 62 year male past medical history of severe chronic obstructive pulmonary disease on chronic prednisone and azithromycin (follows with Dr.), history of left upper lobe resection 2015, hypertension, prediabetes who presents today with worsening fevers shortness of breath since 11/15/2021.  Patient tested himself at home with an over-the-counter test on 11/19/2021 which was positive for COVID-19.  He is vaccinated and had his 2nd Pfizer dose 03/30/2021.  He did not yet receive the booster vaccine.  Patient's symptoms initially started with fever overall 102 F at home.     In the emergency department he was noted to be hypoxic requiring 3 L nasal cannula, worsening shortness of breath found to have acute on chronic hypoxic respiratory failure in the setting of COVID-19 pneumonia. Initial lab work notable for thrombocytopenia with platelets of 88, likely myelosuppressive manifestation of COVID-19. Chest x-ray demonstrated evidence of pneumonia with mild interstitial prominence.  He was febrile upon arrival as well to 39.4 it was given Toradol and dexamethasone.  He was admitted to Medicine no 11/22/2021 for further workup and management.   He had normal echocardiogram with EF 57% and normal BNP.  He was also noted to have sputum culture from August 2021 positive for Rhizopus and was evaluated by ID outpatient, thought to be contaminant versus colonization. He was treated with dexamethasone and remdesivir.  During his admission his oxygen requirements continued between 2 and 3 L nasal cannula.  Platelets eventually improved.  His blood glucose was mildly elevated on dexamethasone, secondary to steroid induced hyperglycemia, without need for at home insulin on discharge.  Pulmonary rehab was consulted, recommended 3 liters/minute at rest and 6 liters/minute with activity, of supplemental oxygen.  Patient instructed to complete steroid course for outpatient management of COVID-19.    Patient was discharged in stable condition, afebrile, in no acute distress, and with arranged home oxygen medical equipment and instruction of home use medical equipment.
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Acute myocardial infarction, Catheterisation cardiac, Chest pain, Coronary artery stenosis, Dyspnoea
Clinical narrative: On June 7, 2021 at around 1700 hrs. experienced crushing chest pain and extreme SOB  after climbing stairs in my home.  I asked my son to take me to hospital - less than  1 mi. distant. I was diagnosed as having a NSTEMI, placed on heparin drip and transported to Medical Center.  I was placed on a The following day Dr., Chief of Cardiology and Professor of Medicine, performed a coronary angiogram  A 90% mid-LAD stenosis was observed and PCI performed.  A drug eluding metal stent was placed with good result.  I was discharged the following day.
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Stent placement
Clinical narrative: On June 7, 2021 at around 1700 hrs. experienced crushing chest pain and extreme SOB  after climbing stairs in my home.  I asked my son to take me to hospital - less than  1 mi. distant. I was diagnosed as having a NSTEMI, placed on heparin drip and transported to Medical Center.  I was placed on a The following day Dr., Chief of Cardiology and Professor of Medicine, performed a coronary angiogram  A 90% mid-LAD stenosis was observed and PCI performed.  A drug eluding metal stent was placed with good result.  I was discharged the following day.
Age: 38.0
Sex: M
Vaccine: COVID19
Symptoms: Adverse reaction, Palpitations
Clinical narrative: Covid like symptoms as severe as the covid symptoms experienced when I had covid. Heart palpitations that come and go.
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Axillary pain, Mammogram normal, Oedema peripheral, Pain, Ultrasound scan normal
Clinical narrative: Pain left armpit, swelling left armpit. Started in January. Didn't initially associate it with the vaccine.  Got  progressively worse. Went to doctor when it became painful. Visited doctor on March 23, ultrasound at the Hospital, March 31. Second ultrasound and diagnostic mammogram at the clinic April 14. Given all clear by the clinic.
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Blood lactic acid normal, COVID-19, COVID-19 pneumonia, Chest X-ray abnormal
Clinical narrative: Patient discharged from inpatient admission (2) days from  11/21- 11/23/2021.  Patient is a 73-year-old male with a past medical history of mild chronic obstructive pulmonary disease, remote tobacco abuse, coronary artery disease without stents, dyslipidemia, hypertension, BPH, GERD and untreated OSA who presented with chief complaint of increasing shortness of breath in the setting of COVID-19.  He was fully vaccinated.  He lives with his daughter who became ill with COVID 2 weeks prior to admission.  His symptoms began on 11/16/2021 with decreased appetite, decreased energy, nonproductive cough and chest pain with coughing.  The patient had a home COVID test which was positive.  He was being monitored with a home pulse ox and was noted to have an oxygen saturation of 88% on room air.  He was brought to the emergency department.  In the emergency department, he was febrile with a temperature of 38.9°.  Blood pressure was stable.  Oxygen saturation was 86% on room air.  He was placed on 2 L nasal cannula.  Chest x-ray showed bilateral infiltrates consistent with COVID pneumonia.  Labs showed a normal procalcitonin and lactic acid.  Her complete blood count showed a normal white count.  He received Tylenol for his fever and dexamethasone.  He continued on a course of dexamethasone and IV remdesivir.  His oxygen improved to 1 L with rest and 2 L with activity per Pulmonary rehab eval.  He continued to improve symptomatically.  He was discharged home on 11/23/2021.
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Chest pain, Condition aggravated, Cough, Decreased appetite, Dyspnoea
Clinical narrative: Patient discharged from inpatient admission (2) days from  11/21- 11/23/2021.  Patient is a 73-year-old male with a past medical history of mild chronic obstructive pulmonary disease, remote tobacco abuse, coronary artery disease without stents, dyslipidemia, hypertension, BPH, GERD and untreated OSA who presented with chief complaint of increasing shortness of breath in the setting of COVID-19.  He was fully vaccinated.  He lives with his daughter who became ill with COVID 2 weeks prior to admission.  His symptoms began on 11/16/2021 with decreased appetite, decreased energy, nonproductive cough and chest pain with coughing.  The patient had a home COVID test which was positive.  He was being monitored with a home pulse ox and was noted to have an oxygen saturation of 88% on room air.  He was brought to the emergency department.  In the emergency department, he was febrile with a temperature of 38.9°.  Blood pressure was stable.  Oxygen saturation was 86% on room air.  He was placed on 2 L nasal cannula.  Chest x-ray showed bilateral infiltrates consistent with COVID pneumonia.  Labs showed a normal procalcitonin and lactic acid.  Her complete blood count showed a normal white count.  He received Tylenol for his fever and dexamethasone.  He continued on a course of dexamethasone and IV remdesivir.  His oxygen improved to 1 L with rest and 2 L with activity per Pulmonary rehab eval.  He continued to improve symptomatically.  He was discharged home on 11/23/2021.
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Exposure to SARS-CoV-2, Full blood count, Lung infiltration, Lung opacity, Procalcitonin normal
Clinical narrative: Patient discharged from inpatient admission (2) days from  11/21- 11/23/2021.  Patient is a 73-year-old male with a past medical history of mild chronic obstructive pulmonary disease, remote tobacco abuse, coronary artery disease without stents, dyslipidemia, hypertension, BPH, GERD and untreated OSA who presented with chief complaint of increasing shortness of breath in the setting of COVID-19.  He was fully vaccinated.  He lives with his daughter who became ill with COVID 2 weeks prior to admission.  His symptoms began on 11/16/2021 with decreased appetite, decreased energy, nonproductive cough and chest pain with coughing.  The patient had a home COVID test which was positive.  He was being monitored with a home pulse ox and was noted to have an oxygen saturation of 88% on room air.  He was brought to the emergency department.  In the emergency department, he was febrile with a temperature of 38.9°.  Blood pressure was stable.  Oxygen saturation was 86% on room air.  He was placed on 2 L nasal cannula.  Chest x-ray showed bilateral infiltrates consistent with COVID pneumonia.  Labs showed a normal procalcitonin and lactic acid.  Her complete blood count showed a normal white count.  He received Tylenol for his fever and dexamethasone.  He continued on a course of dexamethasone and IV remdesivir.  His oxygen improved to 1 L with rest and 2 L with activity per Pulmonary rehab eval.  He continued to improve symptomatically.  He was discharged home on 11/23/2021.
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia, SARS-CoV-2 test positive, White blood cell count normal
Clinical narrative: Patient discharged from inpatient admission (2) days from  11/21- 11/23/2021.  Patient is a 73-year-old male with a past medical history of mild chronic obstructive pulmonary disease, remote tobacco abuse, coronary artery disease without stents, dyslipidemia, hypertension, BPH, GERD and untreated OSA who presented with chief complaint of increasing shortness of breath in the setting of COVID-19.  He was fully vaccinated.  He lives with his daughter who became ill with COVID 2 weeks prior to admission.  His symptoms began on 11/16/2021 with decreased appetite, decreased energy, nonproductive cough and chest pain with coughing.  The patient had a home COVID test which was positive.  He was being monitored with a home pulse ox and was noted to have an oxygen saturation of 88% on room air.  He was brought to the emergency department.  In the emergency department, he was febrile with a temperature of 38.9°.  Blood pressure was stable.  Oxygen saturation was 86% on room air.  He was placed on 2 L nasal cannula.  Chest x-ray showed bilateral infiltrates consistent with COVID pneumonia.  Labs showed a normal procalcitonin and lactic acid.  Her complete blood count showed a normal white count.  He received Tylenol for his fever and dexamethasone.  He continued on a course of dexamethasone and IV remdesivir.  His oxygen improved to 1 L with rest and 2 L with activity per Pulmonary rehab eval.  He continued to improve symptomatically.  He was discharged home on 11/23/2021.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Extra dose administered
Clinical narrative: Patient not eligible for the booster shot. It had not been 6 months. There was a miscommunication between nursing staff and pharmacy vaccinators.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Blood chloride decreased, Blood creatinine normal, Blood sodium decreased, Blood urea normal
Clinical narrative: Patient discharged after (4) inpatient admission from 11/20-11/24/2021. Patient is a 47 y.o. female with past medical history significant for HTN, HLD, migraines, GERD, depression and anxiety who presents today with chills, fever and cough in setting of known Covid 19 infection. The patient reports first developing fatigue and cough 8 days ago. She has been experiencing intermittent chills and fever over the last five days. She took an at home Covid 19 test which was positive, later confirmed by a PCR. She complains of diffuse myalgias and joint pain. She has also been having loose stool. This morning, the patient woke up with chills and a temperature of 103.8F with nausea, vomiting and shortness of breath, at which time she presented to the ED. The patient is vaccinated.    In the ED, the patient was febrile (T102.7F), tachycardic (HR 107), tachypneic (RR 28) and hypoxic requiring 2LNC. Baseline lab work showed sodium 131, chloride 97, BUN 11, Cr 0.74, WBC 7.19, Hgb 13.5. CXR showed probable left lower lobe infiltrate. The patient received tylenol. IV Rocephin, IV doxycyline, IV decadron, IV toradol, IV morphine and IV zofran while in the ED. She will be admitted for further management.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Chest X-ray abnormal, Chills, Cough, Diarrhoea
Clinical narrative: Patient discharged after (4) inpatient admission from 11/20-11/24/2021. Patient is a 47 y.o. female with past medical history significant for HTN, HLD, migraines, GERD, depression and anxiety who presents today with chills, fever and cough in setting of known Covid 19 infection. The patient reports first developing fatigue and cough 8 days ago. She has been experiencing intermittent chills and fever over the last five days. She took an at home Covid 19 test which was positive, later confirmed by a PCR. She complains of diffuse myalgias and joint pain. She has also been having loose stool. This morning, the patient woke up with chills and a temperature of 103.8F with nausea, vomiting and shortness of breath, at which time she presented to the ED. The patient is vaccinated.    In the ED, the patient was febrile (T102.7F), tachycardic (HR 107), tachypneic (RR 28) and hypoxic requiring 2LNC. Baseline lab work showed sodium 131, chloride 97, BUN 11, Cr 0.74, WBC 7.19, Hgb 13.5. CXR showed probable left lower lobe infiltrate. The patient received tylenol. IV Rocephin, IV doxycyline, IV decadron, IV toradol, IV morphine and IV zofran while in the ED. She will be admitted for further management.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspnoea, Fatigue, Haemoglobin normal, Hypoxia, Lung infiltration
Clinical narrative: Patient discharged after (4) inpatient admission from 11/20-11/24/2021. Patient is a 47 y.o. female with past medical history significant for HTN, HLD, migraines, GERD, depression and anxiety who presents today with chills, fever and cough in setting of known Covid 19 infection. The patient reports first developing fatigue and cough 8 days ago. She has been experiencing intermittent chills and fever over the last five days. She took an at home Covid 19 test which was positive, later confirmed by a PCR. She complains of diffuse myalgias and joint pain. She has also been having loose stool. This morning, the patient woke up with chills and a temperature of 103.8F with nausea, vomiting and shortness of breath, at which time she presented to the ED. The patient is vaccinated.    In the ED, the patient was febrile (T102.7F), tachycardic (HR 107), tachypneic (RR 28) and hypoxic requiring 2LNC. Baseline lab work showed sodium 131, chloride 97, BUN 11, Cr 0.74, WBC 7.19, Hgb 13.5. CXR showed probable left lower lobe infiltrate. The patient received tylenol. IV Rocephin, IV doxycyline, IV decadron, IV toradol, IV morphine and IV zofran while in the ED. She will be admitted for further management.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Nausea, Pyrexia, SARS-CoV-2 test positive, Tachycardia
Clinical narrative: Patient discharged after (4) inpatient admission from 11/20-11/24/2021. Patient is a 47 y.o. female with past medical history significant for HTN, HLD, migraines, GERD, depression and anxiety who presents today with chills, fever and cough in setting of known Covid 19 infection. The patient reports first developing fatigue and cough 8 days ago. She has been experiencing intermittent chills and fever over the last five days. She took an at home Covid 19 test which was positive, later confirmed by a PCR. She complains of diffuse myalgias and joint pain. She has also been having loose stool. This morning, the patient woke up with chills and a temperature of 103.8F with nausea, vomiting and shortness of breath, at which time she presented to the ED. The patient is vaccinated.    In the ED, the patient was febrile (T102.7F), tachycardic (HR 107), tachypneic (RR 28) and hypoxic requiring 2LNC. Baseline lab work showed sodium 131, chloride 97, BUN 11, Cr 0.74, WBC 7.19, Hgb 13.5. CXR showed probable left lower lobe infiltrate. The patient received tylenol. IV Rocephin, IV doxycyline, IV decadron, IV toradol, IV morphine and IV zofran while in the ED. She will be admitted for further management.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Tachypnoea, Vomiting, White blood cell count normal
Clinical narrative: Patient discharged after (4) inpatient admission from 11/20-11/24/2021. Patient is a 47 y.o. female with past medical history significant for HTN, HLD, migraines, GERD, depression and anxiety who presents today with chills, fever and cough in setting of known Covid 19 infection. The patient reports first developing fatigue and cough 8 days ago. She has been experiencing intermittent chills and fever over the last five days. She took an at home Covid 19 test which was positive, later confirmed by a PCR. She complains of diffuse myalgias and joint pain. She has also been having loose stool. This morning, the patient woke up with chills and a temperature of 103.8F with nausea, vomiting and shortness of breath, at which time she presented to the ED. The patient is vaccinated.    In the ED, the patient was febrile (T102.7F), tachycardic (HR 107), tachypneic (RR 28) and hypoxic requiring 2LNC. Baseline lab work showed sodium 131, chloride 97, BUN 11, Cr 0.74, WBC 7.19, Hgb 13.5. CXR showed probable left lower lobe infiltrate. The patient received tylenol. IV Rocephin, IV doxycyline, IV decadron, IV toradol, IV morphine and IV zofran while in the ED. She will be admitted for further management.
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Blood pressure decreased, Blood pressure measurement
Clinical narrative: Blood pressure dropped significantly within 15 minutes of receiving shot. This reaction occurred with both shots (2nd shot, 2/13/2021, Lot # EL9284).
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Abdominal distension, Abdominal pain, Anal incontinence, Urinary incontinence, Weight decreased
Clinical narrative: severe abdominal pain; Bloating ;  Passing fluids, both ends;  resulting in a 4.6 Lb weight loss in a six hour period
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Hypoaesthesia, Paraesthesia
Clinical narrative: Numbness in both legs, moderate pain in hip joints, tingling is both feet.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Incorrect dose administered, No adverse event, Product administration error
Clinical narrative: Reporting is for a vaccine administration error where an adult patient was administered the Pfizer-BioTech vaccine  5-11 years   formulation(Orange cap),resulting in a lower than authorized dose for a booster. There is currently no symptoms or adverse event. Patient has been called and correct age appropriate dose of Pfizer-Biotech vaccine has been given as per CDC and vaccine manufacturers
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Acute respiratory failure, Alanine aminotransferase normal, Angiogram pulmonary normal, Anion gap
Clinical narrative: Patient discharged after (4) day inpatient admission from 11/18-11/22/2021.  Patient is a 90 y.o. female with pmhx relevant for HTN, CKD 3a, hypothyroidism, essential tremor, and GERD admitted for acute hypoxic respiratory failure secondary to COVID-19 pneumonia. She is vaccinated x2. Symptoms started 11/10. Received dexamethasone from 11/19, Remdesivir was declined by the patient. Is discharged without home oxygen, she has been weaned back to room air. Due to no longer requiring oxygen dexamethasone is discontinued at discharge. CT-A chest without evidence of PE. Due to worsening respiratory status relatively late in viral course and weakly elevated procalcitonin she was covered for community acquired pneumonia with ceftriaxone and doxycycline from 11/19. Will prescribe augmentin 875 mg BID for 3 more doses (tonight and tomorrow) to complete five days of therapy. Patient has been cleared from COVID isolation requirements due to time from symptom onset. Her home chronic conditions were well controlled and medications unchanged at discharge. A RUQ US was obtained on admission for concerns of abdominal pain which subsided. The imaging did demonstrate cholelithiasis without evidence of acute cholecystitis, and expectant management is indicated. She did have some wheezing on auscultation and nebulizer treatments were initiated.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Arteriosclerosis coronary artery, Aspartate aminotransferase normal, Atelectasis, Bacterial test, Blood albumin decreased
Clinical narrative: Patient discharged after (4) day inpatient admission from 11/18-11/22/2021.  Patient is a 90 y.o. female with pmhx relevant for HTN, CKD 3a, hypothyroidism, essential tremor, and GERD admitted for acute hypoxic respiratory failure secondary to COVID-19 pneumonia. She is vaccinated x2. Symptoms started 11/10. Received dexamethasone from 11/19, Remdesivir was declined by the patient. Is discharged without home oxygen, she has been weaned back to room air. Due to no longer requiring oxygen dexamethasone is discontinued at discharge. CT-A chest without evidence of PE. Due to worsening respiratory status relatively late in viral course and weakly elevated procalcitonin she was covered for community acquired pneumonia with ceftriaxone and doxycycline from 11/19. Will prescribe augmentin 875 mg BID for 3 more doses (tonight and tomorrow) to complete five days of therapy. Patient has been cleared from COVID isolation requirements due to time from symptom onset. Her home chronic conditions were well controlled and medications unchanged at discharge. A RUQ US was obtained on admission for concerns of abdominal pain which subsided. The imaging did demonstrate cholelithiasis without evidence of acute cholecystitis, and expectant management is indicated. She did have some wheezing on auscultation and nebulizer treatments were initiated.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Blood alkaline phosphatase increased, Blood bilirubin normal, Blood calcium decreased, Blood chloride normal, Blood creatinine normal
Clinical narrative: Patient discharged after (4) day inpatient admission from 11/18-11/22/2021.  Patient is a 90 y.o. female with pmhx relevant for HTN, CKD 3a, hypothyroidism, essential tremor, and GERD admitted for acute hypoxic respiratory failure secondary to COVID-19 pneumonia. She is vaccinated x2. Symptoms started 11/10. Received dexamethasone from 11/19, Remdesivir was declined by the patient. Is discharged without home oxygen, she has been weaned back to room air. Due to no longer requiring oxygen dexamethasone is discontinued at discharge. CT-A chest without evidence of PE. Due to worsening respiratory status relatively late in viral course and weakly elevated procalcitonin she was covered for community acquired pneumonia with ceftriaxone and doxycycline from 11/19. Will prescribe augmentin 875 mg BID for 3 more doses (tonight and tomorrow) to complete five days of therapy. Patient has been cleared from COVID isolation requirements due to time from symptom onset. Her home chronic conditions were well controlled and medications unchanged at discharge. A RUQ US was obtained on admission for concerns of abdominal pain which subsided. The imaging did demonstrate cholelithiasis without evidence of acute cholecystitis, and expectant management is indicated. She did have some wheezing on auscultation and nebulizer treatments were initiated.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Blood glucose normal, Blood potassium normal, Blood sodium normal, Blood urea increased, Bone demineralisation
Clinical narrative: Patient discharged after (4) day inpatient admission from 11/18-11/22/2021.  Patient is a 90 y.o. female with pmhx relevant for HTN, CKD 3a, hypothyroidism, essential tremor, and GERD admitted for acute hypoxic respiratory failure secondary to COVID-19 pneumonia. She is vaccinated x2. Symptoms started 11/10. Received dexamethasone from 11/19, Remdesivir was declined by the patient. Is discharged without home oxygen, she has been weaned back to room air. Due to no longer requiring oxygen dexamethasone is discontinued at discharge. CT-A chest without evidence of PE. Due to worsening respiratory status relatively late in viral course and weakly elevated procalcitonin she was covered for community acquired pneumonia with ceftriaxone and doxycycline from 11/19. Will prescribe augmentin 875 mg BID for 3 more doses (tonight and tomorrow) to complete five days of therapy. Patient has been cleared from COVID isolation requirements due to time from symptom onset. Her home chronic conditions were well controlled and medications unchanged at discharge. A RUQ US was obtained on admission for concerns of abdominal pain which subsided. The imaging did demonstrate cholelithiasis without evidence of acute cholecystitis, and expectant management is indicated. She did have some wheezing on auscultation and nebulizer treatments were initiated.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, COVID-19 pneumonia, Chest X-ray abnormal, Cholelithiasis, Condition aggravated
Clinical narrative: Patient discharged after (4) day inpatient admission from 11/18-11/22/2021.  Patient is a 90 y.o. female with pmhx relevant for HTN, CKD 3a, hypothyroidism, essential tremor, and GERD admitted for acute hypoxic respiratory failure secondary to COVID-19 pneumonia. She is vaccinated x2. Symptoms started 11/10. Received dexamethasone from 11/19, Remdesivir was declined by the patient. Is discharged without home oxygen, she has been weaned back to room air. Due to no longer requiring oxygen dexamethasone is discontinued at discharge. CT-A chest without evidence of PE. Due to worsening respiratory status relatively late in viral course and weakly elevated procalcitonin she was covered for community acquired pneumonia with ceftriaxone and doxycycline from 11/19. Will prescribe augmentin 875 mg BID for 3 more doses (tonight and tomorrow) to complete five days of therapy. Patient has been cleared from COVID isolation requirements due to time from symptom onset. Her home chronic conditions were well controlled and medications unchanged at discharge. A RUQ US was obtained on admission for concerns of abdominal pain which subsided. The imaging did demonstrate cholelithiasis without evidence of acute cholecystitis, and expectant management is indicated. She did have some wheezing on auscultation and nebulizer treatments were initiated.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Fibrin D dimer increased, Gallbladder enlargement, Glomerular filtration rate normal, Gram stain
Clinical narrative: Patient discharged after (4) day inpatient admission from 11/18-11/22/2021.  Patient is a 90 y.o. female with pmhx relevant for HTN, CKD 3a, hypothyroidism, essential tremor, and GERD admitted for acute hypoxic respiratory failure secondary to COVID-19 pneumonia. She is vaccinated x2. Symptoms started 11/10. Received dexamethasone from 11/19, Remdesivir was declined by the patient. Is discharged without home oxygen, she has been weaned back to room air. Due to no longer requiring oxygen dexamethasone is discontinued at discharge. CT-A chest without evidence of PE. Due to worsening respiratory status relatively late in viral course and weakly elevated procalcitonin she was covered for community acquired pneumonia with ceftriaxone and doxycycline from 11/19. Will prescribe augmentin 875 mg BID for 3 more doses (tonight and tomorrow) to complete five days of therapy. Patient has been cleared from COVID isolation requirements due to time from symptom onset. Her home chronic conditions were well controlled and medications unchanged at discharge. A RUQ US was obtained on admission for concerns of abdominal pain which subsided. The imaging did demonstrate cholelithiasis without evidence of acute cholecystitis, and expectant management is indicated. She did have some wheezing on auscultation and nebulizer treatments were initiated.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Granuloma, Haematocrit normal, Haemoglobin normal, Hepatic atrophy, Hiatus hernia
Clinical narrative: Patient discharged after (4) day inpatient admission from 11/18-11/22/2021.  Patient is a 90 y.o. female with pmhx relevant for HTN, CKD 3a, hypothyroidism, essential tremor, and GERD admitted for acute hypoxic respiratory failure secondary to COVID-19 pneumonia. She is vaccinated x2. Symptoms started 11/10. Received dexamethasone from 11/19, Remdesivir was declined by the patient. Is discharged without home oxygen, she has been weaned back to room air. Due to no longer requiring oxygen dexamethasone is discontinued at discharge. CT-A chest without evidence of PE. Due to worsening respiratory status relatively late in viral course and weakly elevated procalcitonin she was covered for community acquired pneumonia with ceftriaxone and doxycycline from 11/19. Will prescribe augmentin 875 mg BID for 3 more doses (tonight and tomorrow) to complete five days of therapy. Patient has been cleared from COVID isolation requirements due to time from symptom onset. Her home chronic conditions were well controlled and medications unchanged at discharge. A RUQ US was obtained on admission for concerns of abdominal pain which subsided. The imaging did demonstrate cholelithiasis without evidence of acute cholecystitis, and expectant management is indicated. She did have some wheezing on auscultation and nebulizer treatments were initiated.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Kidney small, Kyphosis, Leukocytosis, Lung opacity, Mean cell volume normal
Clinical narrative: Patient discharged after (4) day inpatient admission from 11/18-11/22/2021.  Patient is a 90 y.o. female with pmhx relevant for HTN, CKD 3a, hypothyroidism, essential tremor, and GERD admitted for acute hypoxic respiratory failure secondary to COVID-19 pneumonia. She is vaccinated x2. Symptoms started 11/10. Received dexamethasone from 11/19, Remdesivir was declined by the patient. Is discharged without home oxygen, she has been weaned back to room air. Due to no longer requiring oxygen dexamethasone is discontinued at discharge. CT-A chest without evidence of PE. Due to worsening respiratory status relatively late in viral course and weakly elevated procalcitonin she was covered for community acquired pneumonia with ceftriaxone and doxycycline from 11/19. Will prescribe augmentin 875 mg BID for 3 more doses (tonight and tomorrow) to complete five days of therapy. Patient has been cleared from COVID isolation requirements due to time from symptom onset. Her home chronic conditions were well controlled and medications unchanged at discharge. A RUQ US was obtained on admission for concerns of abdominal pain which subsided. The imaging did demonstrate cholelithiasis without evidence of acute cholecystitis, and expectant management is indicated. She did have some wheezing on auscultation and nebulizer treatments were initiated.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Murphy's sign test, Platelet count normal, Pneumonia, Procalcitonin increased, Protein total normal
Clinical narrative: Patient discharged after (4) day inpatient admission from 11/18-11/22/2021.  Patient is a 90 y.o. female with pmhx relevant for HTN, CKD 3a, hypothyroidism, essential tremor, and GERD admitted for acute hypoxic respiratory failure secondary to COVID-19 pneumonia. She is vaccinated x2. Symptoms started 11/10. Received dexamethasone from 11/19, Remdesivir was declined by the patient. Is discharged without home oxygen, she has been weaned back to room air. Due to no longer requiring oxygen dexamethasone is discontinued at discharge. CT-A chest without evidence of PE. Due to worsening respiratory status relatively late in viral course and weakly elevated procalcitonin she was covered for community acquired pneumonia with ceftriaxone and doxycycline from 11/19. Will prescribe augmentin 875 mg BID for 3 more doses (tonight and tomorrow) to complete five days of therapy. Patient has been cleared from COVID isolation requirements due to time from symptom onset. Her home chronic conditions were well controlled and medications unchanged at discharge. A RUQ US was obtained on admission for concerns of abdominal pain which subsided. The imaging did demonstrate cholelithiasis without evidence of acute cholecystitis, and expectant management is indicated. She did have some wheezing on auscultation and nebulizer treatments were initiated.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Red blood cell count normal, Renal atrophy, Respiratory disorder, Scan with contrast abnormal, Sputum culture
Clinical narrative: Patient discharged after (4) day inpatient admission from 11/18-11/22/2021.  Patient is a 90 y.o. female with pmhx relevant for HTN, CKD 3a, hypothyroidism, essential tremor, and GERD admitted for acute hypoxic respiratory failure secondary to COVID-19 pneumonia. She is vaccinated x2. Symptoms started 11/10. Received dexamethasone from 11/19, Remdesivir was declined by the patient. Is discharged without home oxygen, she has been weaned back to room air. Due to no longer requiring oxygen dexamethasone is discontinued at discharge. CT-A chest without evidence of PE. Due to worsening respiratory status relatively late in viral course and weakly elevated procalcitonin she was covered for community acquired pneumonia with ceftriaxone and doxycycline from 11/19. Will prescribe augmentin 875 mg BID for 3 more doses (tonight and tomorrow) to complete five days of therapy. Patient has been cleared from COVID isolation requirements due to time from symptom onset. Her home chronic conditions were well controlled and medications unchanged at discharge. A RUQ US was obtained on admission for concerns of abdominal pain which subsided. The imaging did demonstrate cholelithiasis without evidence of acute cholecystitis, and expectant management is indicated. She did have some wheezing on auscultation and nebulizer treatments were initiated.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Thyroid atrophy, Ultrasound abdomen abnormal, Wheezing, White blood cell count increased
Clinical narrative: Patient discharged after (4) day inpatient admission from 11/18-11/22/2021.  Patient is a 90 y.o. female with pmhx relevant for HTN, CKD 3a, hypothyroidism, essential tremor, and GERD admitted for acute hypoxic respiratory failure secondary to COVID-19 pneumonia. She is vaccinated x2. Symptoms started 11/10. Received dexamethasone from 11/19, Remdesivir was declined by the patient. Is discharged without home oxygen, she has been weaned back to room air. Due to no longer requiring oxygen dexamethasone is discontinued at discharge. CT-A chest without evidence of PE. Due to worsening respiratory status relatively late in viral course and weakly elevated procalcitonin she was covered for community acquired pneumonia with ceftriaxone and doxycycline from 11/19. Will prescribe augmentin 875 mg BID for 3 more doses (tonight and tomorrow) to complete five days of therapy. Patient has been cleared from COVID isolation requirements due to time from symptom onset. Her home chronic conditions were well controlled and medications unchanged at discharge. A RUQ US was obtained on admission for concerns of abdominal pain which subsided. The imaging did demonstrate cholelithiasis without evidence of acute cholecystitis, and expectant management is indicated. She did have some wheezing on auscultation and nebulizer treatments were initiated.
Age: 54.0
Sex: M
Vaccine: COVID19, VARZOS
Symptoms: Arthralgia, Dizziness, Fatigue, Headache, Injection site pain
Clinical narrative: Headache (significant) Joint aches (significant) Body aches Fatigue Dizziness Fairly normal injection site soreness in both arms (Left-COVID Moderna Booster; Right-Shingles (1st dose)).  One fairly tough day with ramp up and quick recovery afterwards.  - Used ibuprofen fours times in total. - Chicken soup and lots of sleep.
Age: 54.0
Sex: M
Vaccine: COVID19, VARZOS
Symptoms: Pain
Clinical narrative: Headache (significant) Joint aches (significant) Body aches Fatigue Dizziness Fairly normal injection site soreness in both arms (Left-COVID Moderna Booster; Right-Shingles (1st dose)).  One fairly tough day with ramp up and quick recovery afterwards.  - Used ibuprofen fours times in total. - Chicken soup and lots of sleep.
Age: 27.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Intermenstrual bleeding, Menstruation irregular
Clinical narrative: I have experienced a major change in menstraul cycle. It is very concerning now that it is going two months into the same problem. Whenever I ovulate for the month I bleed that entire  week and then still have a period the following week after it stops. This is very inconvenient for me as I don't know when I will start bleeding it's just always a random day while ovulating and now I?m concerned about my fertility and if my cycle will return to normal prior to this vaccine